INTRODUCTION

Previous studies have shown a strong association between hypothyroidism and depressive disorders (1-3). Treatment-resistant depression (TRD) is traditionally defined as depression with inadequate clinical response usually following the traditional antidepressant therapy (4,5). Patients with depression who fail to achieve symptom remission may pose significant clinical challenges and need augmentation pharmacology approach (4,5). We report a patient with TRD, hypothyroidism, and Thr92 Ala-DIO2 polymorphism who has responded well to T3 therapy, given in 3 divided doses.